Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Delayed Quote. Delayed  - 08/30 05:35:06 pm
5002 GBp   +0.95%
08/25 ASTRAZENECA : to divest part of antibiotics business in up to $1.5 b..
08/25 FTSE retreats as pharma stocks fall
08/25 Astra in £1.2bn deal with Pfizer
News SummaryMost relevantAll newsSector news 

AstraZeneca plc : AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S

share with twitter share with LinkedIn share with facebook
share via e-mail
07/25/2013 | 02:26pm CEST

AstraZeneca and Bristol-Myers Squibb today announced they have resubmitted to the U.S. Food and Drug Administration (FDA), a New Drug Application (NDA) for dapagliflozin for the treatment of adults with type 2 diabetes.

The NDA resubmission, which is pending acceptance by the FDA, includes several new studies and additional long-term data (up to four years' duration) from previously submitted studies.

NOTES TO EDITORS About dapagliflozin

Dapagliflozin, an investigational compound, is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), which works independently of insulin. It is currently approved for the treatment of type 2 diabetes in the European Union, Australia, Brazil, Mexico and New Zealand.

About Type 2 Diabetes

In 2012, diabetes was estimated to affect more than 370 million people worldwide. The prevalence of diabetes is projected to reach more than 550 million by 2030. Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. Type 2 diabetes is a chronic disease characterised by insulin resistance and dysfunction of beta cells in the pancreas, leading to elevated glucose levels. Over time, this sustained hyperglycemia contributes to further progression of the disease. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.www.astrazeneca.com

CONTACTS Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Vanessa Rhodes +44 20 7604 8037 (UK/Global)
Ayesha Bharmal +44 20 7604 8034 (UK/Global)
Michele Meixell +1 302 885 2677 (US)
Jacob Lund +46 8 553 260 20 (Sweden)

Colleen Proctor + 44 207 604 8128 mob: +1 302 357 4882
Ed Seage + 44 207 604 8125 mob: +1 302 373 1361

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
08/25 ASTRAZENECA : to divest part of antibiotics business in up to $1.5 billion deal
08/25 FTSE retreats as pharma stocks fall
08/25 Astra in £1.2bn deal with Pfizer
08/25DJPFIZER : to Buy Some Of Astra's Antibiotics -- WSJ
08/25 Pfizer snaps up AstraZeneca's antibiotics arm
08/25 ASTRAZENECA : *berenberg cuts astrazeneca price target to 5550 pence - 'buy'
08/25 ASTRAZENECA : sells off drugs to Pfizer
08/24 ASTRAZENECA : Pfizer met la main sur 60 anti-infectieux et antifongiques pour 1,..
08/24 Pfizer on buying spree with AstraZeneca antibiotics deal
08/24 PFIZER : AstraZeneca to sell antibiotic pills business to Pfizer
More news
Sector news : Pharmaceuticals - NEC
06:16pDJAgrium, Potash Report Merger Talks
04:01pDJOrexigen in Canadian Marketing Pact With Valeant for Diet Drug
08:49aDJBusiness Watch -- WSJ
08/29 Mylan to launch generic EpiPen at half the price of original
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/29 BIOTECH FORUM DAILY DIGEST : Mylan Adjusts Course, Who Is Next Midcap Buyout Tar..
08/26 A Merck Versus Bristol Showdown
08/26 BIOTECH FORUM DAILY DIGEST : Clinton Takes A Swipe At Biotech, Revisiting The Bu..
08/26 Updating My Price Target On Pfizer
08/25 PFIZER AND MEDIVATION : A Good Strategic Fit
Financials ($)
Sales 2016 23 169 M
EBIT 2016 5 728 M
Net income 2016 2 609 M
Debt 2016 11 639 M
Yield 2016 4,35%
P/E ratio 2016 32,17
P/E ratio 2017 29,31
EV / Sales 2016 7,99x
EV / Sales 2017 8,17x
Capitalization 173 471 M
More Financials
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 69,1 $
Spread / Average Target 6,4%
Consensus details
EPS Revisions
More Estimates Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Edward Bradley Senior VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON16.74%328 086
PFIZER INC.8.77%212 965
ROCHE HOLDING LTD.-12.84%212 954
NOVARTIS AG-10.83%208 887
MERCK & CO., INC.19.29%174 236
More Results